6 Conclusion
Our analysis of the FAERS database
identified cardiac AEs for TKIs in a
real-world setting. Our study
found similar cardiovascular adverse effects with TKIs, Patients over 65
whose taking sorafenib, lenvatinib and regorafenib were at increased
risk for developing cardiac AEs. These four TKIs were associated with
increased risk of developing hypertension and cardiac failure.
Furthermore, aortic dissection was a new complication with regorafenib.
Use of lenvatinib may increase the risk of developing acute coronary
syndrome and myocardial infarction. Clinicians should be aware of the
various cardiac AEs associated with TKIs and the assessment of
cardiovascular risk should be done before starting TKI treatments.